Live Attenuated Varicella Vaccine Efficacy Trial Children
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death - in adults with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated meaningful weight loss, this benefit was accompanied by a concerning signal regarding cardiovascular safety.
The Data: Key Findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to an absolute risk increase of 1.6%, meaning for every 100 patients treated with semaglutide for approximately 3.4 years, one additional cardiovascular event occurred. While statistically significant, the clinical significance is still being debated.
| Event | Semaglutide Group (%) | placebo Group (%) |
|---|---|---|
| Cardiovascular Death | 3.7 | 2.5 |
| Non-Fatal Stroke | 2.6 | 1.7 |
| Non-Fatal Myocardial Infarction (Heart Attack) | 3.4 | 2.1 |
| MACE (Major Adverse Cardiovascular Event) | 6.5 | 4.9 |
Who is Affected? Understanding the Patient Population
It’s crucial to understand *who* was included in this trial. Participants had a body mass index (BMI) of 27 or higher, established cardiovascular disease (such as heart attack, stroke, or peripheral artery disease), and were not diagnosed with diabetes. This is a specific population – those with pre-existing heart conditions and obesity – and the findings may not be generalizable to all individuals using semaglutide for weight loss. individuals using semaglutide solely for diabetes management were *not* included in this study.
The average age of participants was 61.3 years, and approximately half were women. This demographic is especially vulnerable to cardiovascular events, making the observed increase even more concerning.
Why Does This Matter? The Implications for Ozempic Use
These findings challenge the widely held belief that semaglutide is a safe and effective weight loss medication for all. The SELECT trial highlights the importance of carefully considering the cardiovascular risk profile of patients before prescribing semaglutide, especially those with pre-existing heart disease. It also underscores the need for ongoing monitoring of cardiovascular health in patients taking the drug.